AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29939885
Drug: Polyhexamethylene biguanide
RxNorm normalized name: Polyhexamethylene Biguanide
DrugBank: Polihexanide (DB12277)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyhexamethylene biguanide (PHMB) solution
Trial: 28473423
Drug: Abatacept 125
RxNorm normalized name: abatacept 125 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abatacept 125 mg subcutaneously weekly for 24 weeks
Trial: 23131717
Drug: 2.0 mg
RxNorm normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg ranibizumab injections monthly for 3 doses
Trial: 12700373
Drug: Paclitaxel-eluting stent
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel-eluting stent (high dose, 3.1 microg per square millimeter)
Trial: 12700373
Drug: Paclitaxel-eluting stent
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel-eluting stent (low dose, 1.3 microg per square millimeter)
Trial: 10839292
Drug: Chemotherapy (fluoropyrimidine-based,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (fluoropyrimidine-based, various routes and schedules)
Trial: 10839292
Drug: No chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No chemotherapy (observation or supportive care)
Trial: 31094482
Drug: Mertenil® at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mertenil® at initial dosage of 10 mg/day (Scheme I)
Trial: 31094482
Drug: Ekvamer® 5/10/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ekvamer® 5/10/10 mg/day (Scheme II)
Trial: 31094482
Drug: Mertenil® 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mertenil® 10 mg/day + Ekvator® 5/10 mg/day (Scheme III)
Trial: 31094482
Drug: Fenofibrate intake
RxNorm normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fenofibrate intake in a dose of 145 mg/day (for TG >2.3 mmol/l)
Trial: 27499527
Drug: Systematic oral
RxNorm normalized name: Integrase Inhibitors, antiinfectives for systematic use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systematic oral care by the researcher
Trial: 27499527
Drug: Oral care
RxNorm normalized name: Oral Care Q4 Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral care by nurses (Control)
Trial: 24810310
Drug: HMB, arginine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMB, arginine and glutamine mixture alongside oral nutritional supplements (n=11)
Trial: 24810310
Drug: Standard nutritional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard nutritional care alongside oral nutritional supplements (n=12)
Trial: 17334592
Drug: LHRH agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LHRH agonist (leuprolide acetate 7.5 mg/month)
Trial: 17334592
Drug: Antiandrogen monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiandrogen monotherapy (bicalutamide 50 mg q.d., nilutamide 150 mg t.i.d., flutamide 250 mg t.i.d.)
Trial: 15527426
Drug: Bright light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright light treatment (white light, 10,000 lux, 1 h daily)
Trial: 15527426
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (red light, 50 lux, 30 min daily)
Trial: 9277070
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B (0.3 mg/kg/d) + Flucytosine (150 mg/kg/d) + Itraconazole (400 mg/d)
Trial: 31090337
Drug: Modified Buyang
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Buyang Huanwu Decoction (in addition to rt-PA intravenous thrombolysis)
Trial: 31090337
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (rt-PA intravenous thrombolysis only)
Trial: 29024233
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg of low-dose aspirin (LDA) plus 4100 U of low molecular weight heparin (LMWH) subcutaneously daily
Trial: 29024233
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg of low-dose aspirin (LDA) alone
Trial: 29024233
Drug: Persistently abnormal
RxNorm normalized name: BD Persist
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Persistently abnormal D-dimer or increased D-dimer after treatment
Trial: 18574553
Drug: Olmesartan medoxomil
RxNorm normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil administered on hemodialysis day (HD day group)
Trial: 18574553
Drug: Olmesartan medoxomil
RxNorm normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil administered on non-dialysis day (non HD day group)
Trial: 15352911
Drug: High-dose induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose induction interferon-alpha2b (5 million units daily for 4 weeks) followed by standard dose therapy (3 million units three times a week for 44 weeks for genotype 1 or 20 weeks for non-genotype 1)
Trial: 15352911
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose therapy (3 million units three times a week for total treatment duration)
Trial: 10404791
Drug: No hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No hormonal replacement therapy (Control)
Trial: 7550205
Drug: Postural drainage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postural drainage and manual chest percussion (Treatment A)
Trial: 7550205
Drug: Breathing through
RxNorm normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breathing through a commercial device with oscillating positive expiratory pressure (Treatment B)
Trial: 6987028
Drug: Metoprolol (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (single oral doses of 25, 50, 75, 100, or 150 mg)
Trial: 6987028
Drug: Metoprolol (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (multiple doses at 25, 50, or 100 mg thrice daily)
Trial: 27761980
Drug: Lactobacillus gasseri
RxNorm normalized name: Lactobacillus Gasseri
DrugBank: Lactobacillus gasseri (DB16543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus gasseri CP2305 administered daily for 4 weeks
Trial: 25833666
Drug: Pharmacist medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist medication review with face-to-face pharmacist prescribing
Trial: 25833666
Drug: Pharmacist medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist medication review with feedback to general practitioner
Trial: 21054515
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (iNO), dosage and duration not specified
Trial: 19824054
Drug: SFC (salmeterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SFC (salmeterol 50 microg/FP 100 microg twice daily)
Trial: 19824054
Drug: FP (fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FP (fluticasone proprionate 200 microg twice daily)
Trial: 10952772
Drug: Gemcitabine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine plus vinorelbine (Gem Vin) at dose level I (1000/25 mg/m(2))
Trial: 10952772
Drug: Gemcitabine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine plus vinorelbine (Gem Vin) at dose level II (1200/25 mg/m(2))
Trial: 10952772
Drug: Gemcitabine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine plus vinorelbine (Gem Vin) at dose level III (1000/30 mg/m(2))
Trial: 9002810
Drug: HEMA‐glutaraldehyde bonding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HEMA‐glutaraldehyde bonding agent
Trial: 9002810
Drug: formamide‐containing bonding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: formamide‐containing bonding agent
Trial: 6238209
Drug: High-dose medroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose medroxyprogesterone acetate (MPA) therapy
Trial: 3539830
Drug: Biostim (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biostim (8 mg daily)
Trial: 3539830
Drug: Biostim (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biostim (2 mg daily)
Trial: 24874316
Drug: Cortexin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortexin (10 mg three times a day intramuscularly, two courses)
Trial: 24874316
Drug: Cortexin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortexin (10 mg three times a day intramuscularly, one course)
Trial: 15720087
Drug: 585 nm
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 585 nm pulsed-dye laser (single treatment)
Trial: 15720087
Drug: 585 nm
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 585 nm pulsed-dye laser (double treatment)
Trial: 15720087
Drug: Control (periorbital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (periorbital region without treatment)
Trial: 12882865
Drug: Hyperbaric oxygenation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygenation (HBO) therapy, applied twice a day, 5 days a week for 2 weeks, each session lasting 90 min at 2.5 ATA.
Trial: 12882865
Drug: Hyperbaric oxygenation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygenation (HBO) therapy
Trial: 10959507
Drug: Long-term treatment
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term treatment protocol (LTP) with 60 microg PGE1, 5 days each week for 4 weeks, followed by twice a week for 4 weeks, then no drugs for 3 months.
Trial: 10959507
Drug: Short-term treatment
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term treatment protocol (STP) with 20 microg on the first day, 40 microg in the afternoon, and 60 microg on the second day, then 60 microg bid for subsequent cycles.
Trial: 8648221
Drug: Subvirion trivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subvirion trivalent influenza vaccine
Trial: 1465038
Drug: 25 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 micrograms oestradiol administered as vaginal pessaries daily for 3 weeks prior to surgery
Trial: 1465038
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered as vaginal pessaries daily for 3 weeks prior to surgery
Trial: 27595110
Drug: Gel containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel containing 3% ethanolic extract of Brazilian green propolis (EEP-B)
Trial: 27595110
Drug: Gel without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gel without EEP-B
Trial: 27595110
Drug: Gel containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel containing EEP-B
Trial: 24744316
Drug: 25 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 g/d RM + 25 g of maltodextrin/d
Trial: 24744316
Drug: 50 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g/d RM + 0 g/d maltodextrin
Trial: 24744316
Drug: 0 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g/d RM + 50 g/d maltodextrin (placebo)
Trial: 24744316
Drug: 25 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 g/d RM
Trial: 24744316
Drug: 50 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g/d RM
Trial: 20167145
Drug: BUD/FM pMDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BUD/FM pMDI 160/9 micrograms twice daily (320/18 micrograms daily)
Trial: 20167145
Drug: BUD/FM pMDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BUD/FM pMDI 320/9 micrograms once daily (evening)
Trial: 20167145
Drug: BUD/FM pMDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BUD/FM pMDI 160/9 micrograms once daily (evening)
Trial: 20167145
Drug: BUD pMDI
RxNorm normalized name: Clove buds
DrugBank: Clove (DB10672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BUD pMDI 320 micrograms once daily (evening)
Trial: 16412352
Drug: Vitamin K(1)
RxNorm normalized name: vitamin K 1
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K(1) group (10 mg per day for 2 to 7 days, antenatal administration)
Trial: 16412352
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no vitamin K(1) treatment)
Trial: 8645026
Drug: Anti-emetic administration
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-emetic administration group
Trial: 8645026
Drug: Placebo administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administration group
Trial: 1463154
Drug: i.v. midazolam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. midazolam (17 patients; 2.85 +/- 0.84 mg)
Trial: 1463154
Drug: sublingual flunitrazepam
RxNorm normalized name: flunitrazepam
DrugBank: Flunitrazepam (DB01544)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sublingual flunitrazepam (16 patients; 0.005 mg/kg)
Trial: 24953293
Drug: Rush oral
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rush oral immunotherapy (OIT) with peanuts, ingested 3-5 times a day every 30 minutes, increasing the dose by 20% each time, goal dose 3.5-7 g
Trial: 22706327
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 1200 mg twice daily
Trial: 20148372
Drug: Albuterol plus
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol plus caffeine placebo
Trial: 20148372
Drug: Albuterol with
RxNorm normalized name: albuterol with CFC 90 mcg/inh inhalation aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol with 3 mg/kg caffeine
Trial: 20148372
Drug: Albuterol with
RxNorm normalized name: albuterol with CFC 90 mcg/inh inhalation aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol with 6 mg/kg caffeine
Trial: 20148372
Drug: Albuterol with
RxNorm normalized name: albuterol with CFC 90 mcg/inh inhalation aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol with 9 mg/kg caffeine
Trial: 10525070
Drug: Chlorprothixene administered
RxNorm normalized name: chlorprothixene
DrugBank: Chlorprothixene (DB01239)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorprothixene administered intravenously
Trial: 10525070
Drug: Chlorprothixene administered
RxNorm normalized name: chlorprothixene
DrugBank: Chlorprothixene (DB01239)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorprothixene administered orally
Trial: 7551370
Drug: Y-24180 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Y-24180 (20 mg twice a day)
Trial: 233160
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose fluphenazine decanoate (1.25 mg to 5.0 mg biweekly)
Trial: 26338891
Drug: High-Fructose Corn
RxNorm normalized name: High Fructose Corn Syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Fructose Corn Syrup (HFCS55)
Trial: 16525572
Drug: Ximelagatran plus
RxNorm normalized name: XIMELAGATRAN
DrugBank: Ximelagatran (DB04898)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ximelagatran plus ASA (36 mg and 72 mg)
Trial: 16525572
Drug: Ximelagatran plus
RxNorm normalized name: XIMELAGATRAN
DrugBank: Ximelagatran (DB04898)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ximelagatran plus ASA (72 mg)
Trial: 14514744
Drug: Monthly Qa
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly Qa plus standard surveillance (dynamic venous pressure and physical examination)
Trial: 14514744
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group (monthly Qa plus standard surveillance)
Trial: 14514744
Drug: Aspirin (ASA)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (ASA) therapy at baseline
Trial: 9048387
Drug: General endotracheal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General endotracheal anesthesia with epidural augmentation (Group II)
Trial: 7861794
Drug: DUI treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DUI treatment program
Trial: 998633
Drug: Filtered intravenous
RxNorm normalized name: FILTER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filtered intravenous solutions
Trial: 998633
Drug: Unfiltered intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unfiltered intravenous solutions (Control)
Trial: 28314326
Drug: Second-line therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-line therapy (with maintenance)
Trial: 25676422
Drug: Imatinib 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib 800 mg and IM 400 mg plus interferon α (IFN)
Trial: 17969467
Drug: Low-dose alcohol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose alcohol (0.03% BAC) after extended wakefulness (18-21 hours awake)
Trial: 17969467
Drug: Low-dose alcohol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose alcohol (0.03% BAC) in a non-sleep-deprived state
Trial: 17969467
Drug: High-dose alcohol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose alcohol (0.05% BAC) in a rested state
Trial: 15155300
Drug: Intrathecal midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intrathecal midazolam 2 mg, fentanyl 10 micro g
Trial: 15155300
Drug: Fentanyl 10
RxNorm normalized name: FENTANYL 100MCG/HR PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 10 micro g
Trial: 15155300
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of intrathecal midazolam and fentanyl
Trial: 9174307
Drug: Patient-controlled propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient-controlled propofol sedation (PCS) combined with a basal infusion of propofol (n = 15)
Trial: 9174307
Drug: Neurolept analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurolept analgesia using an initial bolus dose of fentanyl (0.7 microg/kg) and droperidol (0.04 mg/kg) followed by a fentanyl infusion (n = 15)
Trial: 1532586
Drug: Estrogen treatment
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen treatment (oral ethinylestradiol, 150 micrograms daily + intramuscular polyestradiol phosphate, 80 mg/mo)
Trial: 29331663
Drug: Oxaliplatin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin (200 mg/M2)
Trial: 26769788
Drug: e‐assessed postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: e‐assessed postoperative recovery follow‐up daily for 14 days via smartphone app including the Swedish web‐version of Quality of Recovery (SwQoR)
Trial: 22257543
Drug: EC‐MPS 1,440
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EC‐MPS 1,440 mg/d with reduced tacrolimus (n = 46)
Trial: 22257543
Drug: EC‐MPS 720
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EC‐MPS 720 mg/d with unchanged tacrolimus (n = 48)
Trial: 22257543
Drug: EC‐MPS 1,440
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EC‐MPS 1,440 mg/d
Trial: 22257543
Drug: EC‐MPS 720
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EC‐MPS 720 mg/d
Trial: 15811735
Drug: Oral acetazolamide
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acetazolamide 500 mg 1 hour preoperatively followed by 250 mg every 6 hours
Trial: 15811735
Drug: Topical brinzolamide
RxNorm normalized name: Brinzolamide
DrugBank: Brinzolamide (DB01194)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topical brinzolamide 1% 1 drop every 12 hours starting immediately after speculum removal
Trial: 15811735
Drug: No ocular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No ocular hypotensive medication (Control group)
Trial: 11966940
Drug: New formulation
RxNorm normalized name: TRIPROLIDINE HYDROCHLORIDE 1.25 mg in 1 mL ORAL SYRUP [HISTEX PD Drops New Formulation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New formulation CLOtest
Trial: 7620694
Drug: Vagimid 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vagimid 500 tablets (500 mg metronidazole)
Trial: 7620694
Drug: Vagimid vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vagimid vaginal tablets (100 mg metronidazole)
Trial: 7399805
Drug: Husband participation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Husband participation in all treatment sessions
Trial: 23322527
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (Risperidone tablet; Dr. Reddy's Laboratories Ltd.)
Trial: 23322527
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (Risperdal(®) tablet; Xian‐Janssen Pharmaceutical Ltd.)
Trial: 21262278
Drug: Alcohol administration
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol administration in a laboratory experiment